secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-020833
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology Q1 net loss $19.2M; cash $150.8M; ODD for PYX-201 in pancreatic cancer
--------------------------------------------------------------------------------

- Net loss of $19.2M ($0.54 per share) vs $31.4M ($0.97) in Q1 2022; R&D expenses $11.9M, G&A $9.1M.
- Cash, equivalents, restricted cash and short-term investments $150.8M, no debt; runway into 1H 2025.
- FDA granted Orphan Drug Designation for PYX-201 in pancreatic cancer; Phase 1 trial dosing underway.
- Phase 1 trial of PYX-106 dosing expected to begin Q2 2023; preliminary data from both trials late 2023 to early 2024.
- One-time $8M payment to Pfizer in Q1 for FACT platform license expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023020833/0000950170-23-020833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023020833/pyxs-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer